US Stock MarketDetailed Quotes

TNXP Tonix Pharmaceuticals

Watchlist

0.1883
-0.0005-0.26%

Close Nov 27 16:00 ET

0.1905
+0.0022+1.17%

Post 20:01 ET

35.19MMarket Cap-2P/E (TTM)

Tonix Pharmaceuticals Stock Forum

Angelos

14 hours ago

$Tonix Pharmaceuticals (TNXP.US)$
#TNXP - Expected earnings Tonix Pharmaceuticals Holding Corp
Tonix Pharmaceuticals Holding Corp. (TNXP) is expected to report $-2.03 for Q3 2024

Angelos

14 hours ago

$Tonix Pharmaceuticals (TNXP.US)$
#TNXP - Expected earnings Tonix Pharmaceuticals Holding Corp
Tonix Pharmaceuticals Holding Corp. (TNXP) is expected to report $-2.03 for Q3 2024

Goldman Sachs

14 hours ago

$Tonix Pharmaceuticals (TNXP.US)$
#TNXP - Expected earnings Tonix Pharmaceuticals Holding Corp
Tonix Pharmaceuticals Holding Corp. (TNXP) is expected to report $-2.03 for Q3 2024

Goldman Sachs

15 hours ago

$Tonix Pharmaceuticals (TNXP.US)$ https://youtu.be/v_VIj3lMETU?si=mKwShpRtJb54IFS2

我要向钱看

15 hours ago

CONTINUE FROM PREVIOUS UPDATE

$Tonix Pharmaceuticals (TNXP.US)$ Dr. Seth Lederman, CEO of Tonix Pharmaceuticals (NASDAQ:TNXP), joined Steve Darling from Proactive to unveil promising results at the ACR Convergence 2024 Annual Meeting from the company’s Phase 3 RESILIENT trial of its proprietary sublingual bedtime medication for fibromyalgia. The trial met its primary endpoint, achieving a statistically significant reduction in daily pain compared to a placebo.
Additionally, the treatment demonstr...